Molecular Systems Biology · 2012 · 282 citations · 51 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyDrug InteractionsPharmacokinetic ModelingAdverse Drug Event DetectionAdverse Drug Reaction DetectionAdverse Drug Reaction PredictionDrug Interaction ModelingDrug-drug Interactions In MetabolismPharmacodynamic ModelingAdverse Drug Event PredictionAdverse Drug EventsArea Under The Receiver Operating Characteristic CurveCross-validationDrug Interaction Prediction ModelsDrug Interaction Severity PredictionPharmacokinetic Interaction PredictionReceiver Operating Characteristic Analysis
Inferring drug‑drug interactions is essential for drug development and administration, yet most computational methods focus only on pharmacokinetic CYP‑related interactions. The authors present INDI, a method that infers both CYP‑related pharmacokinetic and non‑CYP pharmacodynamic drug interactions. INDI models these interactions and estimates severity levels for each DDI, indicating that severe interactions are common in clinical practice. Cross‑validation yields an AUC ≥0.93, and application to FDA adverse event data links 53% of events to known or predicted DDIs, with 18% of hospitalized patients receiving severe interactions, making INDI a useful web tool for clinicians and pharmaceutical companies.
Inferring drug-drug interactions (DDIs) is an essential step in drug development and drug administration. Most computational inference methods focus on modeling drug pharmacokinetics, aiming at interactions that result from a common metabolizing enzyme (CYP). Here, we introduce a novel prediction method, INDI (INferring Drug Interactions), allowing the inference of both pharmacokinetic, CYP-related DDIs (along with their associated CYPs) and pharmacodynamic, non-CYP associated ones. On cross validation, it obtains high specificity and sensitivity levels (AUC (area under the receiver-operating characteristic curve) ≥0.93). In application to the FDA adverse event reporting system, 53% of the drug events could potentially be connected to known (41%) or predicted (12%) DDIs. Additionally, INDI predicts the severity level of each DDI upon co-administration of the involved drugs, suggesting that severe interactions are abundant in the clinical practice. Examining regularly taken medications by hospitalized patients, 18% of the patients receive known or predicted severely interacting drugs and are hospitalized more frequently. Access to INDI and its predictions is provided via a web tool at http://www.cs.tau.ac.il/~bnet/software/INDI, facilitating the inference and exploration of drug interactions and providing important leads for physicians and pharmaceutical companies alike.
51
Gene Ontology: tool for the unification of biology
Michael Ashburner, Catherine A. Ball, Judith A. Blake et al. · Nature Genetics · 2000 · 44.6K citations · Full text
Towards a proteome-scale map of the human protein–protein interaction network
Jean‐François Rual, K. Venkatesan, Tong Hao et al. · Nature · 2005 · 3K citations
DrugBank: a knowledgebase for drugs, drug actions and drug targets
David S. Wishart, Craig Knox, An Chi Guo et al. · Nucleic Acids Research · 2007 · 2.9K citations · Full text
A Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome
Ulrich Stelzl, Uwe Worm, Christian Haenig et al. · Cell · 2005 · 2.4K citations · Full text